OmniComm Systems (Ft. Lauderdale, FL) announced that it has been selected by an unnamed biopharmaceutical company to provide eClinical solutions for two of its Phase I HIV studies involving over 100 patients. Both HIV studies are expected to run for seven months. The company has already used OmniComm Systems in different therapeutic areas.
OmniComm recently announced acquisitions of EDC assets of ERT and Logos Technologies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.